Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Travere Therapeutics, Inc. Trends and Insights

PTC vs Travere: SG&A Expense Trends Unveiled

__timestamp	PTC Therapeutics, Inc.	Travere Therapeutics, Inc.
Wednesday, January 1, 2014	44820000	59644696
Thursday, January 1, 2015	82080000	79541000
Friday, January 1, 2016	97130000	98015000
Sunday, January 1, 2017	121271000	103958000
Monday, January 1, 2018	153548000	103654000
Tuesday, January 1, 2019	202541000	128951000
Wednesday, January 1, 2020	245164000	135799000
Friday, January 1, 2021	285773000	149883000
Saturday, January 1, 2022	325998000	220206000
Sunday, January 1, 2023	332540000	265542000

Unleashing insights

SG&A Expenses: A Tale of Two Therapeutics

In the competitive landscape of biotechnology, understanding the financial health of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of PTC Therapeutics, Inc. and Travere Therapeutics, Inc. from 2014 to 2023. Over this period, PTC Therapeutics has seen a staggering 642% increase in SG&A expenses, peaking at approximately $332 million in 2023. In contrast, Travere Therapeutics experienced a 345% rise, reaching around $266 million in the same year.

Key Insights

Growth Trajectory: PTC Therapeutics consistently outpaced Travere in SG&A growth, reflecting its aggressive expansion strategy.
Strategic Investments: The significant rise in expenses suggests both companies are heavily investing in marketing and administrative capabilities to bolster their market positions.
Future Implications: As these companies continue to grow, monitoring SG&A trends will be vital for investors and stakeholders to gauge operational efficiency and strategic direction.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025

Similar Statistics

Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.

SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.

Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.

Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.

Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc.

PTC Therapeutics, Inc. vs Merus N.V.: SG&A Expense Trends

PTC Therapeutics, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?

Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.

Operational Costs Compared: SG&A Analysis of Veracyte, Inc. and Travere Therapeutics, Inc.

HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?

Iovance Biotherapeutics, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?

Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.